Evelo Biosciences, Inc.
EVLO
$0.00
$0.00-20.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 41.41% | 16.72% | -7.65% | 22.98% | -0.01% |
| Total Depreciation and Amortization | -60.14% | -4.72% | -14.91% | 7.39% | -8.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.37% | 53.97% | -43.01% | -3.02% | 25.59% |
| Change in Net Operating Assets | 13.11% | -376.36% | 125.41% | -424.79% | 266.64% |
| Cash from Operations | 47.51% | 2.21% | 12.57% | -2.67% | 14.85% |
| Capital Expenditure | -- | 100.00% | 94.74% | -2,433.33% | 96.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 94.74% | -2,433.33% | 96.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -99.26% | 631.13% | -99.16% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -- | 100.00% | -111.44% | 161.50% | -99.16% |
| Foreign Exchange rate Adjustments | -172.22% | -205.88% | -97.01% | 155.58% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 146.74% | 3.05% | 3.04% | 8.03% | -143.82% |